Zantac Lawsuit: Four Companies, Two Very Different Courts

Four companies sold Zantac over four different stretches of time, and each now sits in a completely different legal position. One paid out $2.2 billion. Another just watched 80,000 of its cases get thrown out of court in a single ruling — the same week a fourth track, in federal court, is still waiting on an appeal that’s been pending since 2022.

Quick answer: Lawsuits allege that ranitidine (Zantac) degrades into NDMA, a probable carcinogen, causing bladder, stomach, and other cancers. Which lawsuit applies to you depends on which company sold your Zantac and when: GSK (original brand) settled roughly 80,000 claims for up to $2.2 billion (October 2024, accessible only through the ten firms that negotiated it); Sanofi (OTC rights, 2017–2020) resolved over 10,000 cases through confidential settlements worth $200–250 million; Boehringer Ingelheim (OTC rights, 2006–2017) just had more than 80,000 Delaware cases dismissed on April 13, 2026 for lack of admissible causation evidence — a different set of 80,000 cases than GSK’s settlement; and the separate federal MDL remains on hold pending an Eleventh Circuit appeal argued in October 2025, with no ruling yet.

What’s Actually Being Alleged

Ranitidine, the active ingredient in Zantac, can degrade over time — especially with heat or extended storage — into NDMA (N-nitrosodimethylamine), classified as a probable human carcinogen. The FDA requested that all ranitidine products, prescription and over-the-counter alike, be withdrawn from the U.S. market in April 2020 over this contamination concern. Lawsuits allege bladder, stomach, esophageal, liver, and other cancers linked to long-term use, and that the manufacturers knew or should have known about the degradation risk without adequately warning consumers.

Four Companies, Four Different Eras

Unlike most mass torts on this site, this litigation doesn’t involve one manufacturer or even two — the Zantac brand changed hands multiple times, and which company you’d potentially sue depends on when you used the product:

• GlaxoSmithKline (GSK) — developed and marketed prescription and early OTC Zantac.
• Pfizer — held OTC marketing rights for a period before 2006.
• Boehringer Ingelheim — held OTC rights from 2006 to 2017.
• Sanofi — acquired OTC rights in 2017 and marketed the product until the 2020 withdrawal.

Each company’s litigation is now in a genuinely different posture, which is the rest of this guide.

GSK: Settled at Scale, But Not Open to Everyone

On October 9, 2024, GSK reached agreements with ten specific plaintiff firms representing roughly 80,000 claimants, for an aggregate payment of up to $2.2 billion, with disbursement continuing through 2025 and into 2026. Because this resolved through individual firm agreements rather than a class-wide claims process, it’s accessible only if you’re already represented by one of those ten firms — there is no open registration process to join it now.

Sanofi: Confidential Settlements, No Published Figure

Sanofi took a different approach, resolving cases through confidential individual settlements. In May 2024, it agreed to pay between $200 million and $250 million to resolve more than 10,000 lawsuits. As with any confidentially settled mass tort, no single published number describes what an individual case was actually worth.

Boehringer Ingelheim: 80,000 Delaware Cases, Dismissed

This is the most recent, and most consequential, development. On April 13, 2026, a Delaware Superior Court judge dismissed more than 80,000 lawsuits against Boehringer Ingelheim for lack of admissible general-causation evidence — applying to every case filed before December 1, 2025. This followed a July 10, 2025 Delaware Supreme Court ruling holding that the trial court had applied too permissive a standard in initially allowing the plaintiffs’ expert testimony. On remand, the plaintiffs were denied leave to fix their expert reports, and the resulting exclusion effectively ended the bulk of Delaware’s Zantac docket against this one defendant. This is exactly the kind of Daubert-driven dismissal our guide to the Tylenol autism litigation describes in a federal context — though unlike that litigation, no appellate reversal of this Delaware ruling has been reported as of this writing.

This is a different set of roughly 80,000 cases than GSK’s settlement above. The similar round number is coincidental: one is a funded $2.2 billion settlement against GSK, the other is an outright dismissal with no payment against Boehringer Ingelheim. Don’t assume a family member’s or your own case falls into one group just because you’ve heard “80,000 Zantac cases” in the news.

The Separate Federal MDL: Still Waiting on an Appeal Filed in 2022

A third, independent track exists in federal court. The multidistrict litigation, centralized in the Southern District of Florida, was effectively ended on December 6, 2022, when U.S. District Judge Robin L. Rosenberg issued a 341-page opinion excluding all ten of the plaintiffs’ general-causation experts as unreliable — a ruling with real structural similarities to the two state-court Daubert battles described above. Plaintiffs appealed to the Eleventh Circuit, which heard oral argument on October 10, 2025. As of this writing, no decision has been issued, and several hundred federal cases remain in a holding pattern awaiting that ruling. See our explainer on how mass tort litigation actually works for what a Rule 702/Daubert exclusion generally does to a docket, and our guide to the Bard IVC filter litigation for another mass tort where multiple manufacturers ended up in entirely different postures within the same underlying allegation.

Practical Steps

1. Identify exactly which company’s product you used, and roughly when — this determines which of the four tracks above actually applies to your situation.
2. If you believe GSK’s settlement applies to you, confirm whether you’re already represented by one of the ten participating firms — there’s no way to newly register for that specific fund.
3. Don’t assume the Delaware dismissal or the federal MDL exclusion ends your options — each is specific to a particular defendant or court, not a ruling that no Zantac claim can ever succeed.
4. Gather records establishing product use and a documented cancer diagnosis, since general causation disputes make specific documentation more important, not less.
5. Check your state’s statute of limitations, typically two to four years from diagnosis but subject to state-specific discovery rules.
6. Consult an attorney who can identify which specific company and court track your situation falls into, given how differently each is positioned.

Sources & Further Reading

• Delaware Superior Court — April 13, 2026 order in In re: Zantac (Ranitidine) Litigation, dismissing cases against Boehringer Ingelheim, following the Delaware Supreme Court’s reversal in the same matter (2025)
• U.S. District Court, Southern District of Florida — In re: Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924, Judge Robin L. Rosenberg’s opinion (2022) excluding general-causation experts, now on appeal to the U.S. Court of Appeals for the Eleventh Circuit
• U.S. Food and Drug Administration — April 2020 request for market withdrawal of all ranitidine products
• See our guides to how mass tort litigation actually works for what a Rule 702/Daubert exclusion generally does to a docket, the Tylenol autism litigation for a similar causation-expert exclusion that was later reversed on appeal, and the Bard IVC filter litigation for another mass tort where different manufacturers ended up in very different legal postures